ttyh2l Antibody

What is TTYH2 and why is it a target for antibody-based research?

TTYH2 is a member of the tweety family of proteins, functioning as a Ca²⁺-activated large conductance chloride (Cl⁻) channel containing five transmembrane regions. Its significance lies in several key biological functions:

• Participation in Ca²⁺ signal transduction pathways

• Potential roles in cell proliferation and aggregation

• Upregulation in colon carcinoma, suggesting involvement in regulating both proliferation and metastatic potential of colorectal cancer

• Possible implications in kidney tumorigenesis

• Subject to regulation by the ubiquitin-protein ligase Nedd4-2, which binds to and ubiquitinates TTYH2, thereby modulating its cell surface expression and total cellular levels

These diverse functions make TTYH2 an important target for antibody-based research, particularly in studies exploring ion channel regulation, cell proliferation, and cancer biology.

What are the key considerations when selecting an antibody against TTYH2?

When selecting a TTYH2 antibody for research applications, several critical factors should be evaluated:

• Epitope specificity: Determine which region of TTYH2 the antibody targets. Some antibodies recognize specific amino acid sequences (e.g., AA 455-534 or AA 60-110), which may affect recognition of different protein isoforms or conformations .

• Host species and clonality: Consider whether a polyclonal or monoclonal antibody is more suitable for your experimental needs. Polyclonal antibodies offer broader epitope recognition but potentially lower specificity, while monoclonal antibodies provide higher specificity for a single epitope .

• Validated applications: Verify that the antibody has been validated for your specific application (Western blot, ELISA, immunohistochemistry, or immunofluorescence) .

• Cross-reactivity profile: Check the species cross-reactivity (human, mouse, rat) to ensure compatibility with your experimental model .

• Conjugation status: Determine whether you need an unconjugated antibody or one conjugated to a detection tag (HRP, biotin, FITC) based on your experimental design .

• Validation data quality: Assess the quality and comprehensiveness of validation data provided by the supplier to ensure reliability .

How do post-translational modifications of TTYH2 affect antibody selection and experimental design?

Post-translational modifications of TTYH2, particularly ubiquitination, can significantly impact antibody selection and experimental design:

• Ubiquitination: TTYH2 is regulated by Nedd4-2-mediated ubiquitination, which affects its cell surface expression and total cellular levels. When studying TTYH2 regulation, antibodies that can distinguish between ubiquitinated and non-ubiquitinated forms may be necessary .

• Membrane localization: As a transmembrane protein, TTYH2's conformation and accessibility depend on its membrane integration. This affects epitope availability and necessitates appropriate sample preparation methods when using antibodies for detection .

• Phosphorylation status: Consider potential phosphorylation sites that might alter antibody binding or protein function. Phospho-specific antibodies may be required for studying signaling pathways involving TTYH2.

• Glycosylation considerations: Heavily glycosylated proteins often present challenges for antibody generation and detection. When working with TTYH2, be aware that glycosylation patterns may affect epitope recognition .

What are the optimal protocols for using TTYH2 antibodies in Western blotting applications?

For optimal Western blotting results with TTYH2 antibodies, follow these methodological guidelines:

• Sample preparation:

  • For membrane proteins like TTYH2, use lysis buffers containing mild detergents (e.g., 1% Triton X-100 or CHAPS)

  • Include protease inhibitors to prevent degradation

  • Human kidney tissue lysate is recommended as a positive control

• Protein separation:

  • Use 8-12% SDS-PAGE gels for optimal resolution of TTYH2 (expected MW ~58.8 kDa)

  • Run at lower voltage (80-100V) to improve separation

• Transfer conditions:

  • Transfer to PVDF membranes (preferred over nitrocellulose for hydrophobic membrane proteins)

  • Use semi-dry or wet transfer methods at 30V overnight at 4°C for large proteins

• Blocking and antibody incubation:

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

  • Dilute primary TTYH2 antibody at 1:1000-1:5000 in blocking buffer

  • Incubate overnight at 4°C with gentle agitation

  • Wash thoroughly (4×5 minutes with TBST)

  • Incubate with appropriate secondary antibody (1:5000-1:10000) for 1 hour at room temperature

• Detection:

  • Use enhanced chemiluminescence (ECL) for most applications

  • Expect a band at approximately 58.8 kDa for full-length TTYH2

How should TTYH2 antibodies be validated for research applications?

Comprehensive validation of TTYH2 antibodies is crucial for ensuring experimental reliability:

• Western blot validation:

  • Test on multiple relevant tissue/cell lysates (kidney tissue is recommended)

  • Confirm single band at expected molecular weight (58.8 kDa)

  • Include positive and negative controls

  • Verify specificity using knockdown/knockout samples if available

• Immunohistochemistry validation:

  • Test on multiple tissue types with known TTYH2 expression

  • Compare to RNA expression data from databases

  • Verify specificity with blocking peptides (e.g., PEP-1437 can be used with PA5-34395)

• Immunofluorescence validation:

  • Confirm subcellular localization is consistent with membrane protein

  • Co-localize with known membrane markers

  • Include appropriate controls for secondary antibody

• Cross-reactivity testing:

  • Test against related protein family members (TTYH1, TTYH3)

  • Verify species specificity matches supplier claims

• Reproducibility assessment:

  • Test multiple antibody lots if possible

  • Compare results across different experimental conditions

What strategies can be employed to generate high-quality monoclonal antibodies against TTYH2?

Generating high-quality monoclonal antibodies against TTYH2 requires specialized approaches, particularly due to its complex membrane topology and potential glycosylation:

• Antigen design and expression:

  • Use eukaryotic expression systems to preserve native post-translational modifications

  • Express TTYH2 in mammalian cells to ensure proper folding and glycosylation

  • Consider using specific domains (extracellular loops) rather than the entire protein

  • For heavily glycosylated portions, recombinant proteins expressed in eukaryotic cells are preferable over synthetic peptides

• Immunization strategy:

  • Employ a prime-boost protocol with alternating antigen forms

  • Monitor antibody titers throughout immunization to determine optimal harvesting time

  • Consider using conserved epitopes if cross-reactivity between species is desired

• Hybridoma production and screening:

  • Use a methodical approach similar to that described for CD45 antibody generation

  • Screen with multiple assays (ELISA, Western blot, flow cytometry) to select functional antibodies

  • Implement only 1 cell fusion and 2 cyclic sub-cloning steps, which may be sufficient for generating antibodies with satisfactory performance

• Clone selection criteria:

  • Prioritize clones producing antibodies that recognize native conformation

  • Test for functional effects (e.g., ion channel activity modulation)

  • Assess cross-reactivity with related proteins

• Production and purification:

  • Optimize culture conditions for high-yield antibody production

  • Purify using protein G or protein A chromatography to >95% purity

  • Characterize final antibodies for affinity, specificity, and stability

How can TTYH2 antibodies be effectively utilized in immunohistochemistry and immunofluorescence studies?

For optimal results in immunohistochemistry (IHC) and immunofluorescence (IF) studies with TTYH2 antibodies:

• Tissue preparation for IHC:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin using standard protocols

  • Section at 4-6 μm thickness

  • For kidney or colon samples, optimize antigen retrieval methods specifically for membrane proteins

• Antigen retrieval optimization:

  • Test both heat-induced epitope retrieval (HIER) methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 9.0)

  • Determine optimal retrieval time (typically 10-20 minutes)

• Blocking and antibody incubation for IHC:

  • Block endogenous peroxidase with 3% H₂O₂

  • Block non-specific binding with 5-10% normal serum from secondary antibody host species

  • Dilute primary antibody appropriately (typically 1:100-1:500)

  • Incubate overnight at 4°C in a humidified chamber

• Immunofluorescence protocol adjustments:

  • For cultured cells, fix with 4% paraformaldehyde for 10-15 minutes

  • Permeabilize with 0.1-0.3% Triton X-100 for 5-10 minutes

  • Block with 3-5% BSA or normal serum

  • Dilute antibodies in blocking solution

  • Include appropriate counterstains (e.g., DAPI for nuclei, phalloidin for actin)

• Controls and validation:

  • Include positive tissue controls (kidney, colon)

  • Use blocking peptides to confirm specificity

  • Include secondary-only controls

  • Consider dual staining with markers of subcellular compartments to confirm localization

How can TTYH2 antibodies be utilized to investigate the role of TTYH2 in cancer progression?

TTYH2 antibodies can be powerful tools for investigating the role of this protein in cancer progression through several advanced approaches:

• Expression profiling in tumor tissues:

  • Use IHC with TTYH2 antibodies on tissue microarrays spanning multiple cancer types

  • Correlate expression levels with clinical parameters and outcomes

  • Examine colon carcinoma samples, where TTYH2 upregulation has been reported

• Functional studies in cancer cell lines:

  • Combine TTYH2 antibodies with siRNA knockdown to validate specificity

  • Use neutralizing antibodies to block TTYH2 function in vitro

  • Monitor effects on cell proliferation, migration, and colony formation

  • Assess changes in calcium signaling and chloride channel activity

• Signaling pathway analysis:

  • Use TTYH2 antibodies for co-immunoprecipitation to identify binding partners

  • Investigate interactions with ubiquitin-protein ligase Nedd4-2

  • Examine downstream effects on cell cycle regulation and apoptotic pathways

  • Study potential roles in metastatic processes

• In vivo tumor models:

  • Use TTYH2 antibodies to monitor expression in xenograft models

  • Correlate expression with tumor growth rates and metastatic potential

  • Consider therapeutic applications of function-blocking antibodies

• Clinical correlation studies:

  • Develop immunohistochemical scoring systems for TTYH2 expression

  • Correlate with patient survival and treatment response

  • Evaluate potential as a biomarker for specific cancer subtypes

What approaches can be used to study the interactions between TTYH2 and the ubiquitin-protein ligase Nedd4-2?

To investigate the critical interaction between TTYH2 and the ubiquitin-protein ligase Nedd4-2, several specialized methodologies can be employed:

• Co-immunoprecipitation (Co-IP) studies:

  • Use TTYH2 antibodies to pull down protein complexes

  • Immunoblot with Nedd4-2 antibodies to confirm interaction

  • Perform reciprocal Co-IP with Nedd4-2 antibodies

  • Control for specificity using IgG and knockout/knockdown controls

• Proximity ligation assay (PLA):

  • Utilize TTYH2 and Nedd4-2 antibodies from different host species

  • Visualize protein-protein interactions in situ with subcellular resolution

  • Quantify interaction signals under different physiological conditions

• Ubiquitination assays:

  • Immunoprecipitate TTYH2 and blot for ubiquitin

  • Use proteasome inhibitors to enhance detection of ubiquitinated species

  • Examine ubiquitination patterns under various stimuli

  • Map ubiquitination sites using mass spectrometry

• Mutational analysis:

  • Generate TTYH2 mutants lacking potential Nedd4-2 binding motifs

  • Use antibodies to assess changes in ubiquitination and surface expression

  • Examine functional consequences of disrupting the interaction

• Functional consequences assessment:

  • Monitor TTYH2 surface expression using antibody-based flow cytometry

  • Examine changes in chloride channel activity

  • Assess cell proliferation and aggregation under conditions that modify the interaction

How can TTYH2 antibodies contribute to understanding the role of Ca²⁺-activated chloride channels in cellular signaling?

TTYH2 antibodies provide valuable tools for investigating the mechanisms and functions of Ca²⁺-activated chloride channels in cellular signaling:

• Electrophysiological studies with antibody validation:

  • Use TTYH2 antibodies to confirm channel expression in patch-clamp studies

  • Apply function-blocking antibodies to modulate channel activity

  • Correlate electrophysiological recordings with immunolabeling

• Calcium signaling dynamics:

  • Combine calcium imaging with TTYH2 immunolabeling

  • Examine co-localization with calcium channels and stores

  • Investigate the temporal relationship between calcium transients and TTYH2 activity

• Subcellular localization and trafficking:

  • Use immunofluorescence with organelle markers to track TTYH2 localization

  • Study trafficking in response to calcium signals and other stimuli

  • Examine changes in surface expression under various physiological conditions

• Structure-function studies:

  • Employ domain-specific antibodies to investigate channel topology

  • Use antibodies in accessibility assays to probe conformational changes

  • Develop conformation-specific antibodies to capture different functional states

• Tissue-specific expression patterns:

  • Map TTYH2 expression across tissues with potential chloride channel functions

  • Compare with other chloride channel family members

  • Correlate with tissue-specific calcium signaling properties

What role do T follicular helper cells play in functional antibody development, and how might this relate to TTYH2 research?

While not directly related to TTYH2, understanding T follicular helper (Tfh) cell biology has important implications for antibody development against targets like TTYH2:

• T follicular helper cell biology and antibody production:

  • Tfh cells are key drivers of antibody development through their interaction with B cells

  • Different Tfh subsets (Th1-Tfh, Th2-Tfh) have distinct roles in antibody production

  • Th2-Tfh cells activate early during infection and are associated with the functional breadth and magnitude of antibodies

  • Th1-Tfh cells activate later and are associated with plasma cells, which may have a detrimental role in the development of long-lived immunity

• Implications for antibody generation strategies:

  • When developing antibodies against TTYH2, consider immunization protocols that preferentially activate Th2-Tfh cells

  • These could potentially yield antibodies with greater functional diversity and efficacy

  • The timing of antigen exposure and adjuvant selection may influence Tfh subset activation

• Experimental design considerations:

  • Monitor Tfh subset activation during immunization for TTYH2 antibody generation

  • Correlate Tfh responses with antibody quality and functionality

  • Consider experimental models that allow manipulation of Tfh subsets

• Research applications beyond antibody production:

  • Study how modulating TTYH2 function might affect Tfh differentiation and function

  • Investigate whether TTYH2's role in calcium signaling influences Tfh-B cell interactions

  • Explore potential roles of TTYH2 in immune cell function beyond its known involvement in non-immune cells

What are common challenges when working with TTYH2 antibodies, and how can they be addressed?

Several technical challenges may arise when working with TTYH2 antibodies:

• Membrane protein solubilization issues:

  • Challenge: Insufficient solubilization of TTYH2 from membranes

  • Solution: Optimize lysis buffers with different detergents (CHAPS, DDM, or digitonin) and test extraction efficiency by Western blot

• Non-specific binding:

  • Challenge: High background in Western blots or immunostaining

  • Solution: Increase blocking time/concentration, use alternative blocking agents (fish gelatin, casein), and implement more stringent washing procedures

• Epitope masking:

  • Challenge: Reduced detection due to protein-protein interactions or post-translational modifications

  • Solution: Test multiple antibodies targeting different epitopes; modify fixation and antigen retrieval protocols for IHC/IF

• Antibody cross-reactivity:

  • Challenge: Unexpected bands or staining patterns

  • Solution: Validate specificity using TTYH2 knockdown/knockout samples; perform peptide competition assays with immunizing peptide

• Isoform-specific detection:

  • Challenge: Difficulty distinguishing potential TTYH2 isoforms

  • Solution: Use epitope-mapped antibodies targeting specific regions; compare with mRNA expression data for known variants

How should researchers analyze and interpret data from experiments using TTYH2 antibodies?

Proper analysis and interpretation of TTYH2 antibody data requires careful consideration of several factors:

• Western blot quantification:

  • Normalize TTYH2 expression to appropriate loading controls (Na⁺/K⁺-ATPase for membrane fractions)

  • Account for extraction efficiency differences between samples

  • Use standard curves with recombinant TTYH2 for absolute quantification when needed

• Immunohistochemistry scoring:

  • Develop consistent scoring systems for TTYH2 staining intensity and distribution

  • Consider automated image analysis to reduce subjective interpretation

  • Correlate with other approaches (e.g., proteomics, RNA-seq) for validation

• Subcellular localization analysis:

  • Use colocalization coefficients (Pearson's, Mander's) for quantitative assessment

  • Distinguish between surface and intracellular pools of TTYH2

  • Account for cell-to-cell variability in expression patterns

• Functional correlation:

  • Correlate antibody-detected expression levels with functional readouts (e.g., chloride channel activity)

  • Consider post-translational modifications that might affect function but not detection

  • Integrate data across multiple experimental approaches

• Statistical considerations:

  • Apply appropriate statistical tests based on data distribution

  • Account for multiple comparisons when examining TTYH2 across different conditions

  • Consider biological vs. technical replicates in study design

How can researchers distinguish between specific and non-specific binding when using TTYH2 antibodies?

Distinguishing between specific and non-specific binding is critical for reliable results with TTYH2 antibodies:

• Essential controls:

  • Negative controls: Include samples lacking TTYH2 expression (knockout/knockdown)

  • Blocking peptide controls: Pre-incubate antibody with immunizing peptide to block specific binding

  • Isotype controls: Use matched isotype antibodies to identify Fc-mediated binding

  • Secondary-only controls: Exclude primary antibody to detect non-specific secondary binding

• Validation across multiple techniques:

  • Compare results from different applications (WB, IHC, IF, ELISA)

  • Confirm TTYH2 detection correlates with known expression patterns

  • Use multiple antibodies targeting different epitopes

• Signal verification approaches:

  • Titration analysis: Perform antibody dilution series to distinguish specific from non-specific signals

  • Competition assays: Compete with unlabeled antibody or recombinant protein

  • Signal correlation: Compare signal intensity with mRNA levels

• Advanced verification methods:

  • Mass spectrometry identification of immunoprecipitated proteins

  • Super-resolution microscopy to confirm expected subcellular localization

  • Functional validation using channel activity assays

What methodological considerations are important when designing first-in-human studies involving antibodies, and how might this relate to TTYH2 research?

While not directly related to TTYH2 antibodies for research use, understanding principles of first-in-human (FIH) antibody studies provides valuable context for translational research:

• Safety assessment foundations:

  • Robust preclinical data should provide sufficient insight into the full pharmacodynamic pathways

  • Appropriate animal species selection should consider both pharmacokinetic/pharmacodynamic and safety considerations

• Dose selection methodology:

  • The minimal anticipated biological effect level (MABEL) approach is recommended for calculating starting doses, particularly for biotherapeutics with agonistic modes of action

  • For antibodies with antagonistic actions, higher receptor occupancy may be acceptable for starting doses

  • For potential TTYH2-targeting therapeutic antibodies, determining whether target-mediated elimination occurs would be crucial

• Subject monitoring strategies:

  • The "sentinel" group approach is recommended, particularly for first-in-class drugs with potentially profound physiological effects

  • Safety review committees should evaluate data between dosing steps

• TTYH2-specific considerations:

  • As a chloride channel, modulating TTYH2 function could have diverse physiological effects

  • Potential on-target and off-target effects would need careful characterization

  • Tissue cross-reactivity studies comparing human and animal tissues would be essential

• Regulatory guidance evolution:

  • The approach to first-in-human antibody studies has evolved significantly following the TGN1412 incident

  • The proportion of studies using MABEL-based approaches increased significantly after 2011, reflecting updated regulatory guidance

These principles provide important context for researchers working on TTYH2 antibodies with potential therapeutic applications, highlighting the rigorous process required for translating research tools into clinical applications.

What emerging technologies might enhance the development and application of TTYH2 antibodies?

Several cutting-edge technologies are poised to revolutionize TTYH2 antibody development and applications:

• Single B-cell antibody cloning:

  • Rapid cloning of large libraries of monoclonal antibodies directly from patient-derived plasmablasts or memory B-cells

  • Application to generate human monoclonal antibodies with potentially superior properties

  • Accelerated discovery of antibodies targeting conformational epitopes of TTYH2

• Next-generation sequencing of antibody repertoires:

  • Deep sequencing to map the development of antibody responses during immunization

  • Identification of optimal B-cell selection strategies for TTYH2-specific antibodies

  • The VH3-23-D3-3-J4 rearrangement has been identified as potentially important in some protective antibody responses

• Structural biology approaches:

  • Cryo-EM of antibody-TTYH2 complexes to precisely define epitopes

  • Structure-guided antibody engineering for improved specificity and affinity

  • Insights into conformational changes in TTYH2 function

• Antibody-based therapeutics technologies:

  • Antibody-drug conjugates could potentially deliver compounds directly to TTYH2-expressing cells

  • Bi-specific antibodies linking TTYH2 to immune effector cells

  • CAR-T approaches for targeting TTYH2-overexpressing cancer cells

• In vitro display technologies:

  • Phage, yeast, or mammalian display for rapid selection of high-affinity antibodies

  • Directed evolution to enhance specificity and reduce cross-reactivity

  • Selection under defined conditions to identify conformation-specific antibodies

How might TTYH2 antibodies contribute to understanding and treating disease?

TTYH2 antibodies have significant potential for advancing both basic understanding and therapeutic approaches for various diseases:

• Cancer diagnostics and therapeutics:

  • Development of diagnostic tools for cancers with TTYH2 upregulation, particularly colon carcinoma

  • Therapeutic targeting of TTYH2 in cancers where it promotes proliferation or metastasis

  • Biomarker development for patient stratification and treatment monitoring

• Ion channel pathophysiology:

  • Investigation of TTYH2's role in chloride channel-related disorders

  • Exploration of calcium signaling dysregulation in disease contexts

  • Understanding the impact of TTYH2 mutations or expression changes in human pathologies

• Immunomodulatory approaches:

  • Examination of potential interactions between TTYH2 and immune cell function

  • Drawing on principles from T follicular helper cell biology to develop more effective antibody responses

  • Exploration of whether TTYH2 plays roles in immune cell function similar to its role in non-immune cells

• Precision medicine applications:

  • Development of companion diagnostics based on TTYH2 expression or function

  • Correlation of TTYH2 status with treatment outcomes

  • Personalized therapeutic approaches targeting specific TTYH2 variants or expression patterns